Allosteric inhibition of BACE1 by an exosite-binding antibody

Current Opinion in Structural Biology

Volumn 23, Issue 6, 2013, Pages 797-805

  Wang, Weiru ^a   Liu, Yichin ^a   Lazarus, Robert A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BETA SECRETASE 1; BETA SECRETASE 1 ANTIBODY; BETA SECRETASE 1 INHIBITOR; BETA SECRETASE INHIBITOR; CYSTEINE PROTEINASE; ENZYME ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; SERINE PROTEINASE; TAK 070; UNCLASSIFIED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ANTIBODY COMBINING SITE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBSTRATE COMPLEX; HUMAN; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; ANTIBODIES; ASPARTIC ACID ENDOPEPTIDASES; DRUG DESIGN; HUMANS; PROTEASE INHIBITORS;

EID: 84888848645     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2013.08.001     Document Type: Review

References (66)

1. Rawlings N.D., Barrett A.J., Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 2012, 40:D343-D350.
2. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
3. Bai G., Pfaff S.L. Protease regulation: the Yin and Yang of neural development and disease. Neuron 2011, 72:9-21.
4. Peach M.J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977, 57:313-370.
5. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988, 85:4686-4690.
6. Boss C., Richard-Bildstein S., Weller T., Fischli W., Meyer S., Binkert C. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr Med Chem 2003, 10:883-907.
7. Braga-Silva L.A., Santos A.L. Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis. Curr Med Chem 2011, 18:2401-2419.
8. Henningsson F., Yamamoto K., Saftig P., Reinheckel T., Peters C., Knight S.D., Pejler G. A role for cathepsin E in the processing of mast-cell carboxypeptidase A. J Cell Sci 2005, 118:2035-2042.
9. Rochefort H., Capony F., Garcia M., Cavailles V., Freiss G., Chambon M., Morisset M., Vignon F. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis?. J Cell Biochem 1987, 35:17-29.
10. Xin H., Stephans J.C., Duan X., Harrowe G., Kim E., Grieshammer U., Kingsley C., Giese K. Identification of a novel aspartic-like protease differentially expressed in human breast cancer cell lines. Biochim Biophys Acta 2000, 1501:125-137.
11. Chuman Y., Bergman A., Ueno T., Saito S., Sakaguchi K., Alaiya A.A., Franzen B., Bergman T., Arnott D., Auer G., et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999, 462:129-134.
12. Eder J., Hommel U., Cumin F., Martoglio B., Gerhartz B. Aspartic proteases in drug discovery. Curr Pharm Des 2007, 13:271-285.
13. Pokorna J., Machala L., Rezacova P., Konvalinka J. Current and novel inhibitors of HIV protease. Viruses 2009, 1:1209-1239.
14. Jensen C., Herold P., Brunner H.R. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008, 7:399-410.
15. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007, 6:341-342.
16. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
17. Suh Y.H. An etiological role of amyloidogenic carboxyl-terminal fragments of the β-amyloid precursor protein in Alzheimer's disease. J Neurochem 1997, 68:1781-1791.
18. Vassar R. BACE1: the β-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004, 23:105-114.
19. Hu X., He W., Diaconu C., Tang X., Kidd G.J., Macklin W.B., Trapp B.D., Yan R. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J 2008, 22:2970-2980.
20. -/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener 2010, 5:31.
21. McConlogue L., Buttini M., Anderson J.P., Brigham E.F., Chen K.S., Freedman S.B., Games D., Johnson-Wood K., Lee M., Zeller M., et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem 2007, 282:26326-26334.
22. Vassar R., Kandalepas P.C. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res Ther 2011, 3:20-25.
23. Hong L., Turner R.T., Koelsch G., Shin D., Ghosh A.K., Tang J. Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00-3. Biochemistry 2002, 41:10963-10967.
24. Dunn B.M. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem Rev 2002, 102:4431-4458.
25. Hamada Y., Kiso Y. Advances in the identification of β-secretase inhibitors. Expert Opin Drug Discov 2013, 8:709-831.
26. Acquati F., Accarino M., Nucci C., Fumagalli P., Jovine L., Ottolenghi S., Taramelli R. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett 2000, 468:59-64.
27. Saftig P., Hetman M., Schmahl W., Weber K., Heine L., Mossmann H., Koster A., Hess B., Evers M., von Figura K., et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995, 14:3599-3608.
28. Abbenante G., Fairlie D.P. Protease inhibitors in the clinic. Med Chem 2005, 1:71-104.
29. Dash C., Kulkarni A., Dunn B., Rao M. Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Mol Biol 2003, 38:89-119.
30. Umezawa H., Aoyagi T., Morishima H., Matsuzaki M., Hamada M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo) 1970, 23:259-262.
31. Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A.K., Zhang X.C., Tang J. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science 2000, 290:150-153.
32. Ghosh A.K., Gemma S., Tang J. β-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 2008, 5:399-408.
33. Rajendran L., Schneider A., Schlechtingen G., Weidlich S., Ries J., Braxmeier T., Schwille P., Schulz J.B., Schroeder C., Simons M., et al. Efficient inhibition of the Alzheimer's disease β-secretase by membrane targeting. Science 2008, 320:520-523.
34. Kornacker M.G., Lai Z., Witmer M., Ma J., Hendrick J., Lee V.G., Riexinger D.J., Mapelli C., Metzler W., Copeland R.A. An inhibitor binding pocket distinct from the catalytic active site on human β-APP cleaving enzyme. Biochemistry 2005, 44:11567-11573.
35. Atwal J.K., Chen Y., Chiu C., Mortensen D.L., Meilandt W.J., Liu Y., Heise C.E., Hoyte K., Luk W., Lu Y., et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 2011, 3:84ra43.
36. Freund J. Accumulation of antibodies in the central nervous system. J Exp Med 1930, 51:889-902.
37. Watts R.J., Dennis M.S. Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol 2013, 17:393-399.
38. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J.M., Prabhu S., Watts R.J., et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011, 3:84ra44.
39. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967, 425:497-502.
40. Turner R.T., Hong L., Koelsch G., Ghosh A.K., Tang J. Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (β-secretase). Biochemistry 2005, 44:105-112.
41. Tomasselli A.G., Qahwash I., Emmons T.L., Lu Y., Leone J.W., Lull J.M., Fok K.F., Bannow C.A., Smith C.W., Bienkowski M.J., et al. Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J Neurochem 2003, 84:1006-1017.
42. Zhou L., Chavez-Gutierrez L., Bockstael K., Sannerud R., Annaert W., May P.C., Karran E., De Strooper B. Inhibition of β-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J Biol Chem 2011, 286:8677-8687.
43. Hemming M.L., Elias J.E., Gygi S.P., Selkoe D.J. Identification of β-secretase (BACE1) substrates using quantitative proteomics. PLoS ONE 2009, 4:e8477.
44. Gutierrez L.J., Enriz R.D., Baldoni H.A. Structural and thermodynamic characteristics of the exosite binding pocket on the human BACE1: a molecular modeling approach. J Phys Chem A 2010, 114:10261-10269.
45. Kornacker MG, Copeland RA, Hendrick J, Lai Z, Mapelli C, Witmer M, Marcinkeviciene J, Metzler M, Lee VG, Riexinger DJ, et al.: Beta secretase exosite binding peptides and methods for identifying beta secretase modulators. US Patent Application Publication No. US20070149763 A1. 2007.
46. Fukumoto H., Takahashi H., Tarui N., Matsui J., Tomita T., Hirode M., Sagayama M., Maeda R., Kawamoto M., Hirai K., et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 2010, 30:11157-11166.
47. Drag M., Salvesen G.S. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 2010, 9:690-701.
48. Merdanovic M., Monig T., Ehrmann M., Kaiser M. Diversity of allosteric regulation in proteases. ACS Chem Biol 2013, 8:19-26.
49. Hauske P., Ottmann C., Meltzer M., Ehrmann M., Kaiser M. Allosteric regulation of proteases. Chembiochem 2008, 9:2920-2928.
50. Sela-Passwell N., Rosenblum G., Shoham T., Sagi I. Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?. Biochim Biophys Acta 2010, 1803:29-38.
51. Christeller J.T., Farley P.C., Ramsay R.J., Sullivan P.A., Laing W.A. Purification, characterization and cloning of an aspartic proteinase inhibitor from squash phloem exudate. Eur J Biochem 1998, 254:160-167.
52. Ng K.K., Petersen J.F., Cherney M.M., Garen C., Zalatoris J.J., Rao-Naik C., Dunn B.M., Martzen M.R., Peanasky R.J., James M.N. Structural basis for the inhibition of porcine pepsin by Ascaris pepsin inhibitor-3. Nat Struct Biol 2000, 7:653-657.
53. Li M., Phylip L.H., Lees W.E., Winther J.R., Dunn B.M., Wlodawer A., Kay J., Gustchina A. The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix. Nat Struct Biol 2000, 7:113-117.
54. Swain J.F., Gierasch L.M. The changing landscape of protein allostery. Curr Opin Struct Biol 2006, 16:102-108.
55. Nussinov R., Tsai C.J. Allostery in disease and in drug discovery. Cell 2013, 153:293-305.
56. Huber R., Bode W. Structural basis of the activation and action of trypsin. Acc Chem Res 1978, 114-122.
57. Gohara D.W., Di Cera E. Allostery in trypsin-like proteases suggests new therapeutic strategies. Trends Biotechnol 2011, 29:577-585.
58. Lechtenberg B.C., Freund S.M., Huntington J.A. An ensemble view of thrombin allostery. Biol Chem 2012, 393:889-898.
59. Pozzi N., Vogt A.D., Gohara D.W., Di Cera E. Conformational selection in trypsin-like proteases. Curr Opin Struct Biol 2012, 22:421-431.
60. Bock P.E., Panizzi P., Verhamme I.M. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 2007, 5(Suppl. 1):81-94.
61. Eigenbrot C., Kirchhofer D. New insight into how tissue factor allosterically regulates factor VIIa. Trends Cardiovasc Med 2002, 12:19-26.
62. Ganesan R., Eigenbrot C., Kirchhofer D Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochem J 2010, 430:179-189.
63. Mikkelsen J.H., Gyrup C., Kristensen P., Overgaard M.T., Poulsen C.B., Laursen L.S., Oxvig C. Inhibition of the proteolytic activity of pregnancy-associated plasma protein-A by targeting substrate exosite binding. J Biol Chem 2008, 283:16772-16780.
64. Andersen L.M., Andreasen P.A., Svendsen I., Keemink J., Ostergaard H., Persson E. Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways. J Biol Chem 2012, 287:8994-9001.
65. Bannwarth L., Goldberg A.B., Chen C., Turk B.E. Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening. Chem Biol 2012, 19:875-882.
66. The PyMOL Molecular Graphics System, Version 1.5.0.4. Schrödinger, LLC.